In today’s episode, we review the top stories from the second half of 2024. The last six months saw the launch of first-of-its-kind IOLS; the clinical advancement of gene therapies for rare diseases; the FDA approval of a device to treat patients with dry AMD; and introduction of novel OCTA technology.

Learn more about your ad choices. Visit megaphone.fm/adchoices